Hims GLP-1 Side Effects: What to Know About Semaglutide and Tirzepatide

Side effects in a Hims GLP-1 program depend on the exact medication and formulation prescribed, not the telehealth brand alone. Semaglutide and tirzepatide often cause digestive symptoms, while uncommon but serious symptoms need prompt care. 1 2 A licensed clinician can assess whether a GLP-1 medicine fits your health history.

What side effects can occur with GLP-1 treatment from Hims or another telehealth provider?

A telehealth service can coordinate a clinical evaluation and prescription, but it does not determine the pharmacology of the medicine. The key question is whether you are prescribed a GLP-1-based medicine—and which one, at what provider-directed dose, in what formulation, and alongside what other medicines.

Why the medication and formulation matter more than the telehealth brand

Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Both affect appetite regulation and slow gastric emptying, which helps explain both their intended effects and their frequent gastrointestinal adverse effects. FDA-approved labeling for these medicines lists similar digestive symptoms and important safety warnings. 1 2

If a program uses the phrase “GLP-1,” ask for the exact active ingredient, route of administration, pharmacy, and follow-up plan. That is more useful for understanding side effects than assuming all GLP-1 programs are alike. Our overview of GLP-1 side effects explains the broader class pattern.

What are the most common semaglutide and tirzepatide side effects?

The most common effects are digestive. In clinical trials of FDA-approved products, gastrointestinal symptoms were most often reported with both semaglutide and tirzepatide, especially while treatment was being increased. 1 2

Nausea, vomiting, diarrhea, constipation, and stomach discomfort

Nausea, diarrhea, vomiting, constipation, indigestion, abdominal pain, and bloating can occur. These medicines slow stomach emptying, which may leave some people feeling full sooner or make large, rich meals harder to tolerate. FDA labels report that gastrointestinal reactions sometimes led participants to stop treatment in trials. 1 2

Reduced appetite, fatigue, headache, and injection-site reactions

Reduced appetite is expected from the medicine’s mechanism, but it can become a concern if it contributes to poor fluid or food intake. Headache and fatigue are also reported in labeling. Injectable products can cause injection-site reactions; a new or worsening reaction should be discussed with the prescribing clinician. 1 2

Why symptoms may be more noticeable during dose changes

FDA-approved semaglutide and tirzepatide labels use gradual dose-escalation schedules in part to reduce gastrointestinal adverse reactions. Your prescriber—not an online article—should decide whether a symptom calls for monitoring, a dosing change, a pause, or urgent evaluation. 1 2

For a closer look at what patients may notice with tirzepatide, see our guide to tirzepatide side effects.

Which GLP-1 side effects may need urgent medical attention?

Most nausea or constipation is not an emergency, but certain symptoms should not be managed by simply waiting it out. Severe or persistent symptoms need prompt medical assessment, particularly if they suggest pancreatitis, gallbladder disease, dehydration, a serious allergy, or low blood sugar with certain diabetes medicines. 1 2

Severe or persistent abdominal pain

Severe abdominal pain that does not go away, especially if it reaches the back and comes with or without vomiting, can be a warning sign of pancreatitis. Pain in the upper abdomen, fever, yellowing skin or eyes, or clay-colored stools can also point to gallbladder problems. FDA labeling directs patients to contact a clinician promptly for symptoms that may suggest these conditions. 1 2

Persistent vomiting, dehydration, or inability to keep fluids down

Ongoing vomiting or diarrhea can cause dehydration. FDA labels warn that dehydration from gastrointestinal reactions can contribute to acute kidney injury, especially in people with kidney disease or limited fluid intake. Seek timely care if you cannot keep fluids down, are urinating much less than usual, feel faint, or have worsening weakness. 1 2

Symptoms of low blood sugar when used with certain diabetes medicines

GLP-1-based medicines can raise the risk of hypoglycemia when used with insulin or medicines that increase insulin release, such as sulfonylureas. Shakiness, sweating, confusion, dizziness, fast heartbeat, or weakness should be taken seriously, especially for people using those medicines. 1 2

Allergic reactions and other symptoms that warrant prompt care

Trouble breathing, swelling of the face, lips, tongue, or throat, widespread rash, fainting, or severe dizziness can signal a serious allergic reaction and require emergency care. Before starting treatment, tell the clinician about prior reactions to medicines and about personal or family history relevant to the product’s labeled contraindications, including medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. 1 2

How do semaglutide and tirzepatide side effects compare?

Semaglutide and tirzepatide have overlapping side-effect profiles because both act on the GLP-1 pathway. Neither medicine is universally easiest to tolerate; an individual’s experience can vary with dose escalation, medical history, other medicines, meal patterns, and the formulation supplied. 1 2

Semaglutide: Ozempic and Wegovy

Ozempic and Wegovy are FDA-approved semaglutide products with different labeled uses. In the STEP 1 trial of adults with overweight or obesity without diabetes, once-weekly semaglutide 2.4 mg was associated with gastrointestinal adverse events that were usually mild to moderate and occurred most often during or shortly after dose escalation. This was a study of the FDA-approved investigational regimen, and individual results vary. 5

Tirzepatide: Mounjaro and Zepbound

Mounjaro and Zepbound are FDA-approved tirzepatide products with different labeled uses. In SURMOUNT-1, adults with obesity or overweight received tirzepatide 5 mg, 10 mg, or 15 mg once weekly; gastrointestinal adverse events were common and were generally mild to moderate, with more events during dose escalation. This trial does not establish outcomes for compounded formulations, and individual results vary. 6

Why there is no universally easiest GLP-1 to tolerate

Trial averages cannot predict one person’s experience. A clinician can consider your diabetes medicines, kidney function, history of gallbladder or pancreas disease, gastrointestinal symptoms, nutrition, pregnancy plans, and prior medication reactions before deciding whether a GLP-1-based medicine is appropriate. 1 2

Are compounded GLP-1 side effects different from brand-name medication side effects?

The active ingredient may have known class-related risks, but a compounded preparation is not the same product as an FDA-approved brand-name medicine. Compounded drugs are not FDA-approved, so FDA does not review them for safety, effectiveness, or quality before marketing in the same way it reviews approved drugs. 7

Compounded semaglutide via a state-licensed 503A compounding pharmacy

Compounded semaglutide may be prescribed in appropriate circumstances through a licensed provider and dispensed by a state-licensed 503A compounding pharmacy. Ask the prescriber and pharmacy what active ingredient, concentration, route, directions, storage instructions, and supplies are included. FDA has warned that dosing errors with compounded injectable semaglutide can lead to serious adverse events, which makes clear labeling and clinician guidance important. 7 8

Compounded tirzepatide via a state-licensed 503A compounding pharmacy

The same questions matter for compounded tirzepatide: identify the active ingredient, form, pharmacy, labeling, follow-up process, and what to do if side effects occur. Do not assume a compounded preparation has the same FDA-reviewed clinical outcomes, device, concentration, or instructions as an FDA-approved tirzepatide product. 2 7

FDA approval, product quality, and why patients should confirm exactly what they are prescribed

FDA explains that compounded drugs can serve patient needs in certain situations, but they are not FDA-approved. A safer access conversation focuses on a licensed clinician’s evaluation and a state-licensed pharmacy—not unlicensed “research” sellers or products without a valid prescription, clear label, or pharmacy contact information. 7

What can patients discuss with a clinician to help manage GLP-1 side effects?

Discuss symptoms early rather than trying to power through them alone. Hydration and nutrition matter, particularly when nausea, vomiting, diarrhea, or a reduced appetite makes it hard to eat or drink enough. 1 2

Food, hydration, and pacing considerations

Many people find that smaller meals, slower eating, regular fluids, and avoiding meals that are unusually large or high in fat can feel more manageable. These are general comfort measures, not a replacement for clinical guidance; persistent symptoms need a call to the prescribing team. For meal-planning ideas, read what to eat on GLP-1 medication. 1 2

Medications, health conditions, and symptoms to disclose before treatment

Tell the clinician about insulin, sulfonylureas, other weight-management medicines, kidney disease, stomach-emptying problems, gallbladder disease, pancreatitis, diabetic eye disease, allergies, pregnancy plans, and all prescription and nonprescription medicines. These details can change the risk discussion and monitoring plan. 1 2 3 4

Foods patients may find harder to tolerate while taking a GLP-1

There is no universal forbidden-food list. Still, very large meals, heavily fried foods, alcohol in excess, and foods that already trigger reflux or stomach upset may be harder to tolerate for some people because GLP-1-based medicines slow gastric emptying. Contact your clinician if eating or drinking becomes difficult. 1 2

How does GLP-1 treatment work at Chia?

At Chia, treatment begins with a short online health questionnaire and review by a licensed US provider. The process is 100% online, but a prescription is issued only when the provider determines it is clinically appropriate.

Clinician-reviewed online eligibility and prescription decisions

Our providers review your health information, current medicines, goals, and safety considerations. They can also help determine whether reported symptoms need a change in the care plan or a more urgent in-person evaluation. Eligibility for treatment requires clinician review, and a prescription is never guaranteed.

Compounded semaglutide injections and compounded tirzepatide tablets or injections

Chia offers compounded semaglutide injections and compounded tirzepatide in tablets or injections. Medications are compounded in the US by state-licensed 503A compounding pharmacies and shipped to a patient’s door when prescribed. Compounded drugs are not FDA-approved. 7

Provider-guided dosing, microdosing availability, and portal support

Dosing is provider-guided and may be adjusted over time. Chia offers microdosing plans for semaglutide and tirzepatide where clinically appropriate, and patients can message their care team through the patient portal between visits. These compounded drugs are not FDA-approved. 7 Plans and product availability can change, so see the relevant product page for current details.

What should you ask before choosing a GLP-1 telehealth program?

A good program should make the medication, pharmacy, safety plan, and follow-up process clear before you begin. Ask for the exact medication and formulation, not just a broad “GLP-1” label.

• What is the exact active ingredient, dosage form, and route of administration?
• Is the product FDA-approved or compounded, and what does that mean for FDA review?
• Which pharmacy dispenses it, and how can I contact that pharmacy?
• What is included in the total monthly cost, and what may change over time?
• How will the prescribing clinician respond to side effects or refill questions?
• What symptoms require an urgent call, an in-person visit, or emergency care?
• How do my other medicines and medical conditions affect hypoglycemia, dehydration, gallbladder, pancreas, kidney, or allergy risks?

If you are comparing programs, do not choose based on marketing claims alone. Review the medication label, make sure you can reach the prescribing team, and confirm that you understand the follow-up plan. Our article on semaglutide dosing and side effects offers additional background for that conversation.

Keep reading

Weight Management

Cheapest Online Weight Loss Programs: How to Compare Cost, Care, and Safety

Weight Management

GLP-1 Weight Loss Clinics: How to Compare Safety, Cost, and Access